Celltrion’s Remsima SC (biosimilar, infliximab) Receives KFDA’s Approval for Rheumatoid Arthritis

 Celltrion’s Remsima SC (biosimilar, infliximab) Receives KFDA’s Approval for Rheumatoid Arthritis

Celltrion’s Remsima SC (biosimilar, infliximab) Receives KFDA’s Approval for Rheumatoid Arthritis

Shots:

  • The KFDA has approved Celltrion’s Remsima SC for RA while the company is planning to seek approval for IBD within the year through the change permit procedure and is expected to be available to the Korean patients following the completion of the permit for the addition of IBD indications
  • Additionally, Celltrion has filed an application for a Remsima SC in Canada to enter the NA and plans to supply it throughout Canada via Celltrion’s direct sales network. The company is expecting to launch the therapy in the US in 2020 and currently being evaluated in P-III study
  • Remsima SC is the world’s first SC biosimilar referencing Janssen’s Remicade (infliximab) and has received EMA’s approval in Nov’2019

Click here ­to­ read full press release/ article | Ref: Celltrion | Image: Celltrion

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post